/PRNewswire/ The "Transdermal Drug Delivery System Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com s offering. The.
/PRNewswire/ The "Transdermal Drug Delivery System Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com s offering. The.
CHICAGO, May 26, 2022 /PRNewswire/ According to the new market research report "Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions)
/PRNewswire/ According to the new market research report "Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories),.
A non-prescription intranasal application of APTT3X™ formulation will DECREASE the risk of contracting COVID-19 by 150% . APTT3X™ is a self-administered process of swabbing the lower passages of the nose, represents a scalable preventative solution that could slow the spread of COVID-19 on a global scale” Dr. Ernesto Cesar Pinto Leal Junior, ELJ ConsultancyROCKWALL, TEXAS, UNITED STATES, April 21, 2021 /EINPresswire.com/ The efficacy of the APTT3X™ formulation has been validated in a just-completed clinical trial conducted in Brazil under “Black Flag” conditions. The data makes clear the formulation adds an additional layer of protection and decreases the viral load of exposure. The results of the trial continue to support the clinical field data that has been accumulated over the last 14 months with over 2,500 individuals applying APTT3X™ to decrease their risk of contracting COVID-19 (SARS-CoV-2).